COMMUNIQUÉS West-GlobeNewswire

Syneos Health to Present at the 2019 Baird Global Healthcare Conference
13/08/2019
MORRISVILLE, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract [...]
Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
13/08/2019
On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical- [...]
Inspire Medical Systems, Inc. Announces New Brand Identity and Website to Better Reach Prospective Patients Struggling with Sleep Apnea
13/08/2019
MINNEAPOLIS, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]
LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates
13/08/2019
CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in [...]
Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases
13/08/2019
City of Hope awarded California Institute for Regenerative Medicine grant to support ongoing Phase 1 clinical trial NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical- [...]
Establishment Labs Reports Second Quarter 2019 Financial Results
13/08/2019
NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today [...]
BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update
13/08/2019
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: Special High-level FDA Meeting, Continued Progress in NurOwn ® ALS Phase 3 Trial and Progressive MS Phase 2 Trial, ALS Phase 3 Trial [...]
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2019
13/08/2019
Enrollment in Third Cohort of PDA Combination Study is Encouraging Preliminary Efficacy Signals Improve with New Data Regarding Second Cohort Entire $2.3 million Owed under Convertible Notes Converted to Equity [...]
Nephros Announces Listing on Nasdaq Capital Market
13/08/2019
SOUTH ORANGE, NJ, Aug. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial-stage company that develops and sells high performance water purification products to the medical device [...]
ProMIS Neurosciences Announces Second Quarter 2019 Results
13/08/2019
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer’s, ALS and Parkinson’s disease TORONTO and CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- ProMIS [...]
VBL Therapeutics Announces Second Quarter 2019 Financial Results
13/08/2019
Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, [...]
Sol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update
13/08/2019
Top-line generic product revenue of $7.8 million TWIN Phase 3 trials are fully enrolled and remain on track to report results in 4Q19 NESS ZIONA, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. ( [...]
CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University
13/08/2019
TÜBINGEN, Germany and BOSTON, Aug. 13, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered into a Collaborative [...]
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence
13/08/2019
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence C.auris is often multi-drug resistant and new [...]
Trillium Therapeutics Reports Second Quarter 2019 Financial Results
13/08/2019
TORONTO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial [...]
Covetrus Announces Financial Results for Second Quarter of 2019
13/08/2019
Net sales of $1,009 million, relatively flat year-over-year, non-GAAP pro forma organic net sales declined 1% year-over-year In North America, net sales of $552 million, or a 6% increase year-over-year; prescription [...]
AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
13/08/2019
On track to report top line data in Phase II OPTION Study in September 2019 NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the [...]
MediWound Reports Second Quarter 2019 Financial Results
13/08/2019
Total revenues of $20.7 million, driven primarily by the upfront payment from Vericel for NexoBrid ® license agreement BARDA committed additional $21 million to fund NexoBrid ® expanded access treatment protocol [...]
ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
13/08/2019
SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for the quarter ended 30 [...]

Pages